Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.Read the full release here
Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.
